// App-Quantinova.ai

PB1762 : PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Giovanni Martinelli

  • Marco Vignetti

  • Hagop Kantarjian

  • David Gomez-Almaguer

  • Yosuke Minami

  • Herve Dombret

  • Meliessa Hennessy

  • Alexander Vorog

  • Bingxia Wang

  • Josep-Maria Ribera

Medical Centers

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • National Cancer Center Hospital East, Kashiwa/JP

  • Takeda Development Center Americas, Inc.,Lexington,Stati Uniti

  • GIMEMA Research Foundation, Rome, Italy

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • National Cancer Center Hospital, Tokyo, Japan

  • GIMEMA Research Foundation, Rome, Italy

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

  • Takeda Development Center Americas, Inc.,Lexington,Stati Uniti

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • GIMEMA Research Foundation, Rome, Italy

  • Takeda Development Center Americas, Inc.,Lexington,Stati Uniti

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • Leukemia,The University of Texas MD Anderson Cancer Center,HOUSTON,Estados Unidos

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • National Cancer Center Hospital, Tokyo, Japan

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • GIMEMA Research Foundation,Rome,Италия

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • GIMEMA Research Foundation, Rome, Italy

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • National Cancer Center Hospital, Tokyo, Japan

  • GIMEMA Research Foundation, Rome, Italy

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • Institut de Recherche Saint-Louis,Université de Paris, Hôpital Saint-Louis,Paris,Francia

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • GIMEMA Research Foundation, Rome, Italy

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • National Cancer Center Hospital, Tokyo, Japan

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

  • Takeda Development Center Americas, Inc.,Lexington,Stati Uniti

  • Takeda Development Center Americas, Inc.,Lexington,Stati Uniti

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.,Meldola,Italien

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

  • National Cancer Center Hospital East, Kashiwa/JP

  • Hospital Universitario, UANL ,Monterrey, Nuevo Leon,Mexique

Locations

  • United States

  • Italy

  • Mexico

  • Japan

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Paraoxonase 1

  • Abelson murine leukemia viral oncogene homolog

Drug/Treatment

  • Ponatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03589326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved